NAV

Sulfamethoxypyridazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Sulfamethoxypyridazine is a sulphonamide antibiotic indicated in the treatment of gonorrhea, inflammation, urinary tract ulcers, and bronchitis.

Generic Name
Sulfamethoxypyridazine
DrugBank Accession Number
DB13773
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 280.3
Monoisotopic: 280.063011436
Chemical Formula
C11H12N4O3S
Synonyms
  • Sulfamethoxypyridazine
  • sulfametoxipiridazina
External IDs
  • CL-13494
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Sulfamethoxypyridazine.
AcenocoumarolThe risk or severity of bleeding can be increased when Sulfamethoxypyridazine is combined with Acenocoumarol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfamethoxypyridazine.
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfamethoxypyridazine.
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamethoxypyridazine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
J01ED05 — Sulfamethoxypyridazine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Aniline and substituted anilines / Alkyl aryl ethers / Pyridazines and derivatives / Organosulfonamides / Imidolactams / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines
show 3 more
Substituents
Alkyl aryl ether / Amine / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonyl group / Ether / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, pyridazines, sulfonamide antibiotic (CHEBI:102516)
Affected organisms
Not Available

Chemical Identifiers

UNII
T034E4NS2Z
CAS number
80-35-3
InChI Key
VLYWMPOKSSWJAL-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N4O3S/c1-18-11-7-6-10(13-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)
IUPAC Name
4-amino-N-(6-methoxypyridazin-3-yl)benzene-1-sulfonamide
SMILES
COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1

References

General References
  1. FDA Thailand: Gana Tab (Sulfamethoxypyridazine) Oral Tablet [Link]
ChemSpider
5139
RxNav
10181
ChEBI
102516
ChEMBL
CHEMBL268869
ZINC
ZINC000000049141
Wikipedia
Sulfamethoxypyridazine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.325 mg/mLALOGPS
logP0.51ALOGPS
logP0.47Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)6.84Chemaxon
pKa (Strongest Basic)2.02Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area107.2 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity72.39 m3·mol-1Chemaxon
Polarizability26.19 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0090000000-eef21c4c7e87b8d3f6d1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0950000000-3e423833b7efb52fb59a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a6r-0910000000-96aacb4b1d0f1ebb5e4c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00b9-0900000000-f9f655290669578f70fc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00fr-0900000000-244cee97931e8b8bbbe8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0290000000-10f30e48bccf3829a90e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0390000000-1e36282b78b1a81ad7d7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-0890000000-892619da5811a1d37033
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0910000000-ef3efe7b6a4c7f15fa3f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-06vl-8970000000-36dc54d1b820c8c77322
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0005-3910000000-18ef5f1355b08d5e82eb
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-178.4626009
predicted
DarkChem Lite v0.1.0
[M-H]-164.60902
predicted
DeepCCS 1.0 (2019)
[M+H]+179.6326009
predicted
DarkChem Lite v0.1.0
[M+H]+166.96704
predicted
DeepCCS 1.0 (2019)
[M+Na]+178.3423009
predicted
DarkChem Lite v0.1.0
[M+Na]+173.06018
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:48 / Updated at May 22, 2021 06:01